A recent mouse model based study suggests that blocking TGF-β may improve osteoporosis treatment by helping quiescent osteoblasts in inactive bone surfaces return to an active state. Using spatial ...

Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, for multiple cancer types, including 1L HPV-negative recurrent/metastatic (R/M) head and neck ...

Schematic representation of different strategies targeting TGF-β signaling for liver fibrosis therapy. TGF-β signaling inhibitors hold important therapeutic potential for hepatic fibrosis. Although ...

Henan Medinno Pharmaceutical Technology Co. Ltd. has synthesized TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer, aging, arteriosclerosis ...

Investigating the association of WNT pathway dysregulation and young-onset colorectal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This abstract does ...

Autotelic Bio presents new TGF-β receptor type-1 inhibitors for cancer Oct. 18, 2023 ...

We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're ...

A recent mouse model based study suggests that blocking TGF-β may improve osteoporosis treatment by helping quiescent osteoblasts in inactive bone surfaces return to an active state.

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal ...